As clinical trials become more complex, sponsors face growing pressure to reach more representative patient populations while ...

The European Commission has granted marketing authorisation to Gilead for Trodelvy (sacituzumab govitecan-hziy) in ...

CHB is a major public health challenge and a leading cause of liver cancer globally. Chronic hepatitis B occurs when the ...

Roche’s Genentech has agreed a deal worth up to $2.3 billion to develop and sell Hanmi Pharmaceutical’s experimental obesity ...

Acadia Pharmaceuticals has secured European Commission approval for DAYBU (trofinetide), opening the door to the first ...

Eli Lilly has announced that orforglipron (Foundayo), its oral glucagon-like peptide-1 (GLP-1) receptor agonist, is now ...

Japanese pharma group Otsuka has signed an agreement to acquire Canada's Mindset Pharma, a specialist in psychedelic medicines for neuropsychiatric disorders. The all-cash deal – worth around C$80 ...

Sanofi is laying off 229 former Blueprint Medicines employees in Cambridge, MA and closing two legacy Blueprint facilities.

Supporting someone living with schizophrenia requires communication, curiosity, and a willingness to listen when their ...

MSD (known as Merck in the United States and Canada) and Moderna have announced positive phase 3 results for intismeran autogene, an mRNA-based individualised neoantigen therapy (INT) for melanoma, in ...

Eric Schadt, a serial entrepreneur and expert in computational biology, is leaving his post as Chief Scientist at Pathos AI ...

First-in-class iberdomide has been given accelerated approval under the Zenbexus brand name, alongside Johnson & Johnson and ...